Company / Operating Income
NeoGenomics Laboratories, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$115.9M
FY2025
5-year range
-$157.6M / -$92.1M
FY2021-FY2025
Trend
-25.8%
vs FY2024
Sector context
#135 of 156
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s operating income of -$116M is lower than 87% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from -$158M in FY2022 to $13M in FY2019.
Based on SEC 10-K filings.
-$116M in FY2025.
Declined from -$108M to -$116M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 156This company -$115.9M Sector average $733.1M
▼
-115.8% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 25.8% year-over-year.
- Ranks #135 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2019.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$115.9M | -25.8% |
| FY2024 | -$92.1M | +14.5% |
| FY2023 | -$107.7M | +31.6% |
| FY2022 | -$157.6M | -32.7% |
| FY2021 | -$118.8M | -748.7% |
| FY2020 | -$14.0M | -207.6% |
| FY2019 | $13.0M | +29.5% |
| FY2018 | $10.0M | +246.0% |
| FY2017 | $2.9M | +34.7% |
| FY2016 | $2.2M | +138.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026